Core Insights - Braskem S.A. is the largest resin producer in the Americas and a leading biopolymers producer globally [1] Financial Performance - The company reported a recurring EBITDA of US$102 million for 4Q24 [2] - Braskem's cash position stands at US$2.4 billion, which ensures coverage of debt maturities over the next 47 months [2] - Operating cash generation for the quarter was US$204 million, approximately R$1.1 billion [2]

Company Performance - Braskem has returned 18.1% year-to-date, significantly outperforming the Oils-Energy sector, which has gained about 3.4% on average [4] - The Zacks Consensus Estimate for Braskem's full-year earnings has increased by 118.7% over the past three months, indicating a strong improvement in analyst sentiment and earnings outlook [3] Industry Ranking - Braskem is part of the Oil and Gas - Integrated - International industry, which currently ranks 137 in the Zacks Industry Rank, with an average gain of 3.7% year-to-date [6] - In contrast, National Fuel Gas, which belongs to the Oil and Gas - Integrated - United States industry, is ranked 74, with the industry moving up by 1.1% this year [7] Sector Context - The Oils-Energy group consists of 247 companies and is currently ranked 3 in the Zacks Sector Rank, which evaluates the average Zacks Rank of individual stocks within the sector [2] - National Fuel Gas has also shown strong performance with a year-to-date return of 19% and a consensus EPS estimate increase of 16.7% over the past three months, holding a Zacks Rank of 1 (Strong Buy) [5]

Group 1 - Braskem (BAK) closed at $5.04, with a 32.6% gain over the past four weeks, and a mean price target of $8.23 suggests a 63.3% upside potential [1] - The average price targets range from a low of $5.40 to a high of $10, with a standard deviation of $2.22, indicating variability among analysts [2] - Analysts show strong agreement on BAK's ability to report better earnings, which supports the potential for stock upside [4][9] Group 2 - The Zacks Consensus Estimate for the current year has increased by 200% over the past month, indicating positive earnings revisions [10] - BAK holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [11] - While consensus price targets may not be reliable for predicting exact gains, they can indicate the direction of price movement [12]

Group 1 - Potbelly Corporation (PBPB) has seen a 14.3% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - Concrete Pumping Holdings, Inc. (BBCP) has experienced a 38.7% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - Braskem S.A. (BAK) has reported a 41.9% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2] Group 2 - Novavax, Inc. (NVAX) has seen a 6.4% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2] - Eton Pharmaceuticals, Inc. (ETON) has experienced a 6.7% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2]

Investors might want to bet on Braskem (BAK) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.The power of a chan ...

For those looking to find strong Oils-Energy stocks, it is prudent to search for companies in the group that are outperforming their peers. Braskem (BAK) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Oils-Energy peers, we might be able to answer that question.Braskem is a member of our Oils-Energy group, which includes 249 different compani ...

Group 1 - The company has a market capitalization of $1.54 billion and is a key player in the petrochemical industry in South [1] - Allka Research has over two decades of experience in investment, focusing on uncovering undervalued assets in various sectors including ETFs, commodities, technology, and pharmaceuticals [1] - The company aims to simplify investment strategies, making them accessible for both seasoned and novice investors [1] Group 2 - Allka Research is committed to delivering substantial returns and strategic insights to its clients [1] - The company seeks to empower individuals financially by sharing its knowledge through Seeking Alpha, contributing analyses and informed perspectives [1] - The mission of Allka Research includes inspiring confidence in readers and fostering a community of informed investors [1]

Investment Strategy - The analyst focuses on value investments, typically targeting companies trading at close to 10x earnings and offering dividend yields [1] - The research primarily covers small-cap and mid-cap companies from the United States, Canada, South America, UK, France, and Germany [1] Company Analysis: Braskem S A - Braskem S A has introduced strategies to reduce emissions and develop more sustainable chemicals, which could attract ESG-focused investors [3] - The company is implementing new initiatives to optimize its assets [3]

Group 1 - Braskem (BAK) has experienced a significant downtrend, with the stock declining 18.8% over the past four weeks due to excessive selling pressure [1] - The stock is currently in oversold territory, indicated by an RSI reading of 19.14, suggesting that the heavy selling may be exhausting itself and a rebound could occur [4] - Analysts are optimistic about Braskem's earnings potential, with a consensus EPS estimate increase of 27.5% over the last 30 days, indicating a strong agreement among sell-side analysts [5] Group 2 - The upward trend in earnings estimate revisions typically leads to price appreciation in the near term, supporting the case for a potential turnaround for Braskem [5] - Braskem holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate trends and EPS surprises, further indicating its potential for recovery [5]

The Petrochemical industry has been a terrible place to invest in for quite some time, with terrible margins and, for many companies in the space, losses quarter after quarter. Braskem (NYSE: BAK ) has been no exception, failing to hitAnalyst’s Disclosure: I/we have a beneficial long position in the shares of BAK either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). ...